Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis

Overview

Journal Int J Environ Res Public Health

Publisher MDPI

Specialties Environmental Health
Public Health

Date 2022 Apr 23

PMID 35457445

Authors

Yan Sun

Zheng Zhu

Jiawei Zhang

Peien Han

Yu Qi

Xiaoyang Wang

Li Yang

Affiliations

Soon will be listed here.

Abstract

The Chinese government has launched six rounds of national drug price negotiation since 2016 to lower the price and expand access to innovative drugs, many of which are anticancer drugs. This study aims to examine the effect of the second round of negotiation at the provincial level on the expenditure, volume, and availability of anti-cancer drugs. Procurement data at the provincial level from January 2017 to September 2018 were extracted from the China Drug Supply Information Platform (CDSIP). The volume, expenditure, and availability of three targeted anti-cancer drugs, rituximab, trastuzumab, and recombinant human endostatin (RHE), in 11 provinces that implemented the policy in September 2017 were analyzed through a controlled interrupted time series (ITS) analysis. A significant 6.0% increase (p < 0.1) in monthly average expenditure, an increase in the volume of 99.51 DDDs (defined daily doses) (p < 0.1), and a 0.24% (p < 0.1) increase in availability were observed for rituximab following the implementation of the policy. The volume and availability of rituximab increased by 949.6 DDDs (p < 0.05) and 1.56%, respectively, immediately after implementation. The availability of trastuzumab increased by 5.14% (p < 0.01) immediately after the implementation while no instant changes in expenditure and volume were observed. A 15% (p < 0.01) increase in monthly expenditure, 3673.17 DDDs increase in volume, and 0.66% increase in availability were observed after the inclusion of Trastuzumab. However, for RHE, only a 0.32% (p < 0.01) increase was observed after its inclusion. Eastern and middle provinces benefited more than western provinces. National negotiation related to the drug price significantly increased the volume and expenditure of anti-cancer drugs and improved their availability. The effect of the policy might be different across different regions and across different anticancer drugs.

Citing Articles

Access to single-inhaler triple medicines for chronic obstructive pulmonary disease in China: a national survey on accessibility and utilisation.

Li W, Guo W, Chen H, Lu W, Yu S, Wang M J Pharm Policy Pract. 2025; 18(1):2466215.

PMID: 40070677 PMC: 11894743. DOI: 10.1080/20523211.2025.2466215.

Impacts of National Reimbursement Drug Price Negotiation on drug accessibility, utilization, and cost in China: a systematic review.

Zhu Z, Zhang J, Xu Z, Wang Q, Qi Y, Yang L Int J Equity Health. 2025; 24(1):36.

PMID: 39905408 PMC: 11796270. DOI: 10.1186/s12939-025-02390-w.

Impact of the National Drug Price Negotiation policy on the price, usage, and affordability of anticancer medicines in Shandong Province, China.

Sun Y, Qiang Y, Duan Y, Song Y Front Public Health. 2025; 12():1368718.

PMID: 39839411 PMC: 11747042. DOI: 10.3389/fpubh.2024.1368718.

Systematic review of the impact of the National Medication Price Negotiated Policy on the accessibility of drugs in China, 2016-2024.

Peng N, Du C, Gong Y, Long X, Wang C, Liu P BMJ Open. 2024; 14(12):e087190.

PMID: 39725414 PMC: 11683965. DOI: 10.1136/bmjopen-2024-087190.

Analysing the effects of National Centralised Drug Procurement and Price Negotiation Policies on novel hypoglycaemic drug usage and costs in Shanghai, China: an interrupted time series analysis.

Song J, Guo W, Jin C, Xu Y, Hu X, Zhang Z BMJ Open. 2024; 14(12):e088318.

PMID: 39627122 PMC: 11624754. DOI: 10.1136/bmjopen-2024-088318.

References

Guan X, Zhang Y, Wushouer H, Shi L, Ross-Degnan D, Wagner A . Differences in reimbursement listing of anticancer therapies in China: an observational study. BMJ Open. 2020; 10(1):e031203. PMC: 6955534. DOI: 10.1136/bmjopen-2019-031203. View

Li H, Liu G, Wu J, Wu J, Dong C, Hu S . Recent Pricing Negotiations on Innovative Medicines Pilot in China: Experiences, Implications, and Suggestions. Value Health Reg Issues. 2018; 15:133-137. DOI: 10.1016/j.vhri.2018.01.009. View

Kwon H, Godman B . Drug Pricing in South Korea. Appl Health Econ Health Policy. 2017; 15(4):447-453. DOI: 10.1007/s40258-017-0307-0. View

Verghese N, Barrenetxea J, Bhargava Y, Agrawal S, Finkelstein E . Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview. J Mark Access Health Policy. 2019; 7(1):1601060. PMC: 6461095. DOI: 10.1080/20016689.2019.1601060. View

Godman B, Bucsics A, Vella Bonanno P, Oortwijn W, Rothe C, Ferrario A . Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Front Public Health. 2018; 6:328. PMC: 6290038. DOI: 10.3389/fpubh.2018.00328. View

Cortes J, Perez-Garcia J, Llombart-Cussac A, Curigliano G, El Saghir N, Cardoso F . Enhancing global access to cancer medicines. CA Cancer J Clin. 2020; 70(2):105-124. DOI: 10.3322/caac.21597. View

Luo Z, Gyawali B, Han S, Shi L, Guan X, Wagner A . Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China. Semin Oncol. 2021; 48(2):141-144. DOI: 10.1053/j.seminoncol.2021.03.001. View

Lagarde M . How to do (or not to do) ... Assessing the impact of a policy change with routine longitudinal data. Health Policy Plan. 2011; 27(1):76-83. DOI: 10.1093/heapol/czr004. View

Fang W, Xu X, Zhu Y, Dai H, Shang L, Li X . Impact of the National Health Insurance Coverage Policy on the Utilisation and Accessibility of Innovative Anti-cancer Medicines in China: An Interrupted Time-Series Study. Front Public Health. 2021; 9:714127. PMC: 8377668. DOI: 10.3389/fpubh.2021.714127. View

10.

Husereau D, Dempster W, Blanchard A, Chambers J . Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs. Value Health. 2014; 17(8):888-94. DOI: 10.1016/j.jval.2014.08.2673. View

11.

Park S, Han E, Kim J, Lee E . Factors influencing the difference between forecasted and actual drug sales volumes under the price-volume agreement in South Korea. Health Policy. 2016; 120(8):867-74. DOI: 10.1016/j.healthpol.2016.06.004. View

12.

Moye-Holz D, van Dijk J, Reijneveld S, Hogerzeil H . The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico. Value Health Reg Issues. 2019; 20:129-135. DOI: 10.1016/j.vhri.2019.04.006. View

13.

Sonik R . Massachusetts Inpatient Medicaid Cost Response to Increased Supplemental Nutrition Assistance Program Benefits. Am J Public Health. 2016; 106(3):443-8. PMC: 4880217. DOI: 10.2105/AJPH.2015.302990. View

14.

Andersen M . Effects of Medicare coverage for the chronically ill on health insurance, utilization, and mortality: Evidence from coverage expansions affecting people with end-stage renal disease. J Health Econ. 2018; 60:75-89. DOI: 10.1016/j.jhealeco.2018.06.002. View

15.

Bernal J, Cummins S, Gasparrini A . Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2016; 46(1):348-355. PMC: 5407170. DOI: 10.1093/ije/dyw098. View

16.

Li B, Li M, Sun L, Wang J, Zheng Y, Hao J . Impact of anticancer drugs price cut on physician's prescription choices on first-line chemotherapy regimens and health expenditure for advanced non-small cell lung cancer in China. J Thorac Dis. 2016; 8(10):2832-2842. PMC: 5107472. DOI: 10.21037/jtd.2016.09.35. View

17.

Huang C, Ung C, Wushouer H, Bai L, Li X, Guan X . Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis. Int J Health Policy Manag. 2021; 11(8):1489-1495. PMC: 9808358. DOI: 10.34172/ijhpm.2021.47. View

18.

Prasad V, De Jesus K, Mailankody S . The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017; 14(6):381-390. DOI: 10.1038/nrclinonc.2017.31. View

19.

Toulemon L . The effect of group purchasing on prices hospitals pay for medicines. Health Econ. 2018; . DOI: 10.1002/hec.3788. View

20.

Ngorsuraches S, Meng W, Kim B, Kulsomboon V . Drug reimbursement decision-making in Thailand, China, and South Korea. Value Health. 2012; 15(1 Suppl):S120-5. DOI: 10.1016/j.jval.2011.11.002. View